Interstitial lung disease in polymyositis and dermatomyositis

Current Opinion in Rheumatology

Volumn 17, Issue 6, 2005, Pages 701-706

  Fathi, Maryam ^a   Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

High resolution computerized tomography; Histopathology; Interstitial lung disease; Myositis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLYCOPROTEIN; KREBS VON DEN LUNGEN 6 GLYCOPROTEIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE COURSE; DISEASE MARKER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SPIROMETRY; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY;

BIOPSY; DERMATOMYOSITIS; HUMANS; INCIDENCE; LUNG; LUNG DISEASES, INTERSTITIAL; POLYMYOSITIS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27544496190     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000179949.65895.53     Document Type: Review

References (46)

1. Mills ES, Mathews WH. Interstitial pneumonitis in dermatomyositis. JAMA 1956; 160:1467-1470.
2. Mori S, Hamada H, Yokoyama A, et al. Severe inclusion body myositis with interstitial pneumonia. Intern Med 2001; 40:940-944.
3. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47:614-622.
4. Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984; 14:60-76.
5. Benbassat J, Gefel D, Larholt K, et al. Prognostic factors in polymyositis/dermatomyositis: a computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985; 28:249-255.
6. Schwarz MI. The lung in polymyositis. Clin Chest Med 1998; 19:701-712.
7. Tazelaar HD, Viggiano RW, Pickersgill J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990; 141:727-733.
8. Takizawa H, Shiga J, Moroi Y, et al. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987; 14:102-107.
9. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63:297-301. A prospective study of 17 patients with PM/DM who were investigated by radiograph/HRCT of the lungs and pulmonary function tests, regardless of clinical symptoms, at the time of diagnosis.
10. Wallaert B, Hatron PY, Grosbois JM, et al. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage: relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis 1986; 133:574-580.
11. Remy-Jardin M, Remy J, Wallaert B, et al. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993; 188:499-506.
12. Trapani S, Camiciottoli G, Vierucci A, et al. Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology (Oxford) 2001; 40:216-220.
13. Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 1974; 65:403-407.
14. Miller FW. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993; 270:1846-1849.
15. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
16. Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford) 2000; 39:632-636.
17. Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/ dermatomyositis. Ann Rheum Dis 2000; 59:257-262.
18. Ihn H, Asano Y, Kubo M, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology (Oxford) 2002; 41:1268-1272.
19. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32:273-284.
20. Sakamoto N, Mukae H, Fujii T, et al. Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis. Intern Med 2004; 43:838-842. A case report of a 49-year-old man with interstitial pneumonia (NSIP) associated with amyopathic DM who failed to respond to therapy.
21. High WA, Cohen JB, Murphy BA, Costner MI. Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis. J Am Acad Dermatol 2003; 49:295-298.
22. Lee CS, Chen TL, Tzen CY, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 2002; 21:391-396.
23. Epler GR, McLoud TC, Gaensler EA, et al. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978; 298:934-939.
24. Muller NL, Staples CA, Miller RR, et al. Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radiology 1987; 165:731-734.
25. Muller NL, Miller RR, Webb WR, et al. Fibrosing alveolitis: CT-pathologic correlation. Radiology 1986; 160:585-588.
26. Nishimura K, Kitaichi M, Izumi T, et al. Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology 1992; 182:337-342.
27. Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol 2004; 49:235-244. Retrospective study of the pattern, distribution, and extent of changes on HRCT of the lungs in patients with PM/DM with ILD.
28. Mino M, Noma S, Taguchi Y, et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997; 169:83-87.
29. Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003; 123:1096-1103.
30. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164:1182-1185.
31. Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47:738-742.
32. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44:585-596. This is an important new contribution to histopathologic characterization of interstitial lung disease in patients with myositis.
33. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199-203.
34. Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162:2213-2217.
35. Lee JS, Im JG, Ahn JM, et al. Fibrosing alveolitis: prognostic implication of ground-glass attenuation at high-resolution CT. Radiology 1992; 184:451-454.
36. Haslam PL, Turton CW, Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35:328-339.
37. Spath M, Schroder M, Schlotter-Weigel B, et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004; 251:859-864. A study looking at the response to treatment and the long-term outcome of 12 patients with PM/DM with anti-Jo 1 antibodies who were evaluated over a mean period of 66.4 months.
38. Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32:58-64. A study of differences in clinical picture and prognosis of 16 patients with PM and 12 patients with DM with ILD.
39. Tjiu JW, Lin SJ, Wang LF, et al. Digital infarcts showing microangiopathy in adult dermatomyositis suggest severe pulmonary involvement and poor prognosis. Br J Dermatol 2004; 150:1214-1216. Report on three cases of DM with multiple digital infarcts with histopathological evidence of microangiopathy in the early course of the disease who developed rapid progressive ILD.
40. Kashiwabara K, Ota K. Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody. Intern Med 2002; 41:584-588.
41. Tubery M, Lauque D, Murris M, et al. Course of interstitial lung diseases associated with inflammatory myopathies: apropos of 5 cases. Ann Med Interne (Paris) 1997; 148:2-10.
42. Tomsic M, Sifrer F. Acute respiratory distress syndrome in a polymyositis patient with the anti-Jo-1 antibody. Wien Klin Wochenschr 2000; 112:728-731.
43. Shinohara T, Hidaka T, Matsuki Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 1997; 36:519-523.
44. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1762-1763.
45. Wilkes M, Sereika S, Fertig N, et al. Treatment of antisynthetae associated interstitial lung disease with tacrolimus in patients with idiopathic inflammatory myopathy. Arthritis Rheum 2003; 48(Suppl):S434.
46. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329:1266. Report on three fatal cases of RA who developed signs of fibrosing alveolitis after three or fewer dosages of infliximab. All three had asymptomatic fibrosing alveolitis before treatment with infliximab.